Medtronic, Inc.

Medtronics, Inc.

Warren L Starkebaum

Mark Turner Rise

Martin T Gerber

John Matthew Swoyer

Gary William King

Michael J Schendel

Roland C Maude-Griffin

Daryle Petersen

Frans L Gielen

Charlene X Yuan

Luiz Geraldo Pivotto

Marc T Stein

David A Dinsmoor

John G Keimel

Charles Randall Rogers

Raymond F McMullen

Jiande Chen

Thomas R Prentice

Gary L Lubben

Benoit Marchal

Tim Herbert

Elizabeth D Firestone

Donald L Hall

Eric H Bonde

Mark A Christopherson

Orhan Soykan

Carl A Schu

Yelena G Tropsha

Daniel J Stetson

Michael O Madsen

Michael Lykke

In some examples, the disclosure relates to a systems, devices, and techniques for delivering electrical stimulation therapy to a patient. In one example, the disclosure relates to a method including delivering a series of pulses with alternating pulse polarities to a gastrointestinal tract of a patient. The series of pulses includes at least a first pulse of a first polarity, a second pulse of a second polarity, and a third pulse of the first polarity, where the first, second and third pulses are delivered in direct succession and in that order. The first and second pulses are separated by a first time delay and the second and third pulses are separated by a second time delay. In some examples, each of the first and second time delays depend on the frequency that the series of pulses are delivered.

Waveforms for electrical stimulation therapy

The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.

Gastric electrical stimulation with lockout interval anti-desensitization feature

Apparatus and techniques to address problems associated with lead migration, patient movement or position, histological changes, neural plasticity or disease progression. Disclosed are techniques for implanting a lead having therapy delivery elements, such as electrodes or drug delivery ports, within a vertebral or cranial bone so as to maintain these elements in a fixed position relative to a desired treatment site. The therapy delivery elements may thereafter be adjusted in situ with a position control mechanism and/or a position controller to improve the desired treatment, such as electrical stimulation and/or drug infusion to a precise target. The therapy delivery elements may be positioned laterally in any direction relative to the targeted treatment site or toward or away from the targeted treatment site. A control system maybe provided for open- or closed-loop feedback control of the position of the therapy delivery elements as well as other aspects of the treatment therapy.

Techniques for positioning therapy delivery elements within a spinal cord or brain

In some examples, electrical stimulation therapy is delivered to support obesity management. The electrical stimulation therapy is configured to cause at least partial gastric distention. Gastric distention tends to induce a sensation of fullness and thereby discourages excessive food intake by the patient. The electrical stimulation therapy may be delivered to the gastrointestinal tract of the patient by electrodes deployed by one or more implantable leads coupled to an electrical stimulator. The electrical stimulator delivers stimulation pulses having a pulse width in a range found to be effective in causing gastric distention.

Electrical stimulation therapy to promote gastric distention for obesity management

A device comprises a medical implant and an actively deployable clip attached to the medical implant that operates to restrict movement of the medical implant once the actively deployable clip is deployed within a body of a patient. In some embodiments, the medical implant is an electrical lead for electrical stimulation. The actively deployable clip is operable to fixate the medical implant to a body tissue once deployed, such that the actively deployable clip performs a similar function to a suture. In this manner, embodiments of the invention may provide a medical implant that requires few or even no sutures to properly fixate the implant within the patient.

Sutureless implantable medical device fixation

The invention is directed toward stimulation of a selected tissue layer. A device is attached to a target tissue by applying vacuum pressure to a vacuum cavity of the device and advancing a needle into tissue within the vacuum cavity. The depth on the vacuum cavity is selected to permit deployment at the selected tissue layer. In one embodiment, the invention is directed toward an implantable medical device comprising a device housing defining a vacuum cavity, and a vacuum port for application of vacuum pressure to draw tissue into the vacuum cavity, an electrode that is movable into the vacuum cavity of the device housing to contact at least a portion of the tissue drawn into the vacuum cavity, and a lead comprising at least one conductor coupled to the electrode.

Selective depth electrode deployment for electrical stimulation

The disclosure is directed to techniques for delivering electrical stimulation therapy to support obesity management. The electrical stimulation therapy is configured to cause at least partial gastric distention. Gastric distention tends to induce a sensation of fullness and thereby discourages excessive food intake by the patient. The electrical stimulation therapy may be delivered to the gastrointestinal tract of the patient by electrodes deployed by one or more implantable leads coupled to an electrical stimulator. The electrical stimulator delivers stimulation pulses having a pulse width in a range found to be effective in causing gastric distention.

Techniques are described that allow an implantable device to sense gastric data and activity data from a patient, and estimate the patient's amount of energy consumed and energy expended based on the sensed data. A system provides feedback to the patient, a family member, or a doctor about the patient's energy consumed, energy expended, and net energy. The data may be provided in table or graphical format, and may show daily or weekly energy balance data or may show a trend of the daily or weekly energy data. The patient may receive feedback by an implanted alert module that provides and audio alert or a vibration alert. In addition, data acquired by the system may be used to adjust the patient's stimulation therapy parameters.

Energy balance therapy for obesity management

A bulking device for implantation into a lumen wall that includes a bulking material that is configured to alter the portion of the lumen into which it is implanted and one or more therapeutic substances in association with the bulking material, wherein the device is configured to alter the portion of the lumen wall into which it is implanted. A method for inserting devices of the invention are also included.

Devices for augmentation of lumen walls

Gastric electrical stimulation with multi-site stimulation anti-desensitization feature

Gastric electrical stimulation with therapy window anti-desensitization feature

A gastro-electric stimulation system includes an INS for producing an electrical stimulation signal, at least one medical electrical lead, and at least two electrical contacts. The medical electrical lead has a proximal end and a distal end, the proximal end being connected to the INS and the distal end being adapted for placement in or near a patient's stomach or appropriate nerve or nerve portion. The electrodes are disposed near the distal end of the medical electrical lead, and the electrodes are electrically connected through the medical electrical lead to the INS to receive the electrical stimulation signal and convey such signal to the selected electrode implant position. The electrical stimulation signal is provided in an amount and manner adapted to decrease the pH of the gastric acid in the patient's stomach and/or to increase the amount of gastric acid produced thereby.

Gastro-electric stimulation for increasing the acidity of gastric secretions or increasing the amounts thereof

A method for treatment of obesity involves implantation of bulking devices within the upper esophageal sphincter (UES) to inhibit swallowing, thereby limiting food intake and treating obesity. One or more bulking devices are implanted within or near the UES to create a partial obstruction, partially impair UES muscle function, or both. The bulking devices make swallowing difficult, limiting the rate of food intake by a patient, and discouraging the patient from quickly consuming an excessive amount of food at one time.

Bulking of upper esophageal sphincter for treatment of obesity

A gastro-electric stimulation system includes an INS for producing an electrical stimulation signal, at least one medical electrical lead, and at least two electrical contacts. The medical electrical lead has a proximal end and a distal end, the proximal end being connected to the INS, the distal end being adapted for placement in or near a patient's stomach or appropriate nerve or nerve portion. The electrodes are disposed near the distal end of the medical electrical lead, and are electrically connected through the medical electrical lead to the INS to receive the electrical stimulation signal and convey such signal to the selected electrode implant position. The electrical stimulation signal is provided in an amount and manner adapted to increase the pH of the gastric acid in the patient's stomach and/or to decrease the amount of gastric acid produced thereby.

Growing community of inventors

Plymouth, MN, United States of America

Warren L Starkebaum